CDKN2A and central nervous system cancer: Cyclin-dependent kinase inhibitor 2A and B (CDKN2A/B) copy number losses (homozygous deletion of CDKN2A-p16INK4α in chromosome 9p) are linked to the activation of the Rb pathway and to the proliferative niches that are observed in gliomas [66].